New Treatment for Advanced Pancreatic Cancer Before Chemotherapy
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a new treatment approach for advanced pancreatic cancer in patients who have never received chemotherapy for their advanced disease. The trial aims to evaluate whether this new strategy can help control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced pancreatic cancer (stage IV) confirmed by biopsy or cell sample
- You have never received chemotherapy for advanced disease (though prior chemotherapy for earlier-stage cancer is allowed if it was over 6 months ago)
- You have measurable tumors on imaging scans that doctors can track
- Your overall health is good enough for treatment (ECOG performance status 0–1, meaning you can do light activities)
- Your blood counts, kidney function, and liver function are adequate for the study drug
- You can undergo safe tumor biopsies (tissue samples) during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LM-108 combined with chemotherapy for people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if it's safe and may help shrink tumors or stop them from growing.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has progressed after prior treatment. The goal is to see if adding immunotherapy can help shrink tumors or slow the cancer down.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
Hear when a new Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.